Author Correction: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells

Acta Pharmacol Sin. 2020 May;41(5):731-732. doi: 10.1038/s41401-019-0341-6.

¹ Department of New Drug Screening Center, China Pharmaceutical University, Nanjing, 210009, China.
² Division of Anti-tumor Pharmacology, Synthetic Organic and Medicinal Chemistry Laboratory, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
³ Synthetic Organic and Medicinal Chemistry Laboratory, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
⁴ Division of Anti-tumor Pharmacology, Synthetic Organic and Medicinal Chemistry Laboratory, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. mygeng@simm.ac.cn.
⁵ Department of Thoracic Surgery, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200336, China. zhengmin8010@126.com.
⁶ Division of Anti-tumor Pharmacology, Synthetic Organic and Medicinal Chemistry Laboratory, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. jding@simm.ac.cn.

^# Contributed equally.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.